HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ritlecitinib

HCID 118115473
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1792180-81-4
Standard SMILES
C=CC(=O)N1C[C@H](Nc2ncnc3[nH]ccc23)CC[C@@H]1C
InChIKey
CBRJPFGIXUFMTM-WDEREUQCSA-N
Molecular formula
C15H19N5O
Average molar mass
285.34 g/mol
Monoisotopic mass
285.15896025

Overview

Ritlecitinib is a pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted at position 4 by a [(3R,6S)-6-methyl-1-(prop-2-enoyl)piperidin-3-yl]amino group. It is a dual inhibitor of Janus kinase 3 and the TEC family of tyrosine kinases. It has a role as an anti-inflammatory drug, an immunosuppressive agent, an antirheumatic drug, a dermatologic drug and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a tertiary carboxamide, a member of acrylamides, a pyrrolopyrimidine, a N-acylpiperidine and a secondary amino compound. It is a conjugate base of a ritlecitinib(1+).

Names & identifiers

Preferred name
Ritlecitinib
IUPAC
1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
English name
Ritlecitinib
Molecular formula
C15H19N5O
Molecular weight
285.34

Names & synonyms

ritlecitinib1792180-81-4PF-066516002OYE00PC251-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-PF06651600PF 066516002-PROPEN-1-ONE, 1-((2S,5R)-2-METHYL-5-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YLAMINO)-1-PIPERIDINYL)-1-((2S,5R)-2-methyl-5-((7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)prop-2-en-1-one1-((2S,5R)-2-methyl-5-(7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)piperidin-1-yl)prop-2-en-1-one1-{(2S,5R)-2-Methyl-5-[(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}prop-2-en-1-one
Show more names
RitlectinibCS-2733EOS-61890Litoxetine (base)Litaxitinib (base)Ritlecitinib, 10 mM in DMSORitlecitinib free base PF-06651600
RefChem:179511JAK3 Inhibitor PF-06651600815-269-71-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-oneRitlecitinib (PF-06651600)1-[(2S,5R)-5-[[7H-Pyrrolo[2,3-d]-4-pyrimidinyl]amino]-2-methyl-1-piperidyl]-2-propen-1-oneMFCD30343868ritlecitinibum

Properties

Computed structural propertiesFilling in

XLogP
2.1
Topological polar surface area
73.9 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
21
Formal charge
0
Complexity
402

Experimental & physicochemical properties

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Breast Feeding; Enzyme Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors

Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Janus Kinase Inhibitors; JAK Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

Physicochemical properties

Density
1.272 · 1.272±0.06 g/cm3(Predicted)
storage temp.
room temp
solubility
100 · DMSO:100.0(Max Conc. mg/mL);350.4(Max Conc. mM)H2O:5.0(Max Conc. mg/mL);17.5(Max Conc. mM)
form
powder
pka
13.03 · 13.03±0.50(Predicted)
color
white to beige
Water Solubility
2 O: · H2O: 5mg/mL, clear (warmed)
InChI
InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1
InChIKey

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesRepr. 2 (100%)

Toxicology

Hepatotoxicity · 1 item

In the prelicensure clinical trials in alopecia areata, serum aminotransferase elevations occurred in 1% to 3% of ritlecitinib treated subjects, but similar rates were found in placebo recipients. The elevations were typically mild and transient, and values above 5 times the upper limit of normal (ULN) occurred in less than 1% of patients. The elevations rarely led to early discontinuations, and often resolved even without dose adjustment. In prelicensure studies in alopecia areata and other autoimmune conditions, there were no instances of liver related severe adverse events or clinically apparent liver injury attributed to ritlecitinib. Since approval and more widescale availability of ritlecitinib, there have been no published reports of hepatotoxicity associated with its use.

Effects During Pregnancy and Lactation · 2 items

◉ Summary of Use during Lactation

◉ Summary of Use during Lactation

Safety data

wgk
WGK 3
Signal word

Chemistry & industry

Pharmacology

ATC Code · 2 items

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingRitlecitinib is 14% bound to plasma proteins.
Pharmacodynamics · 1 item

Ritlecitinib is a kinase inhibitor that promotes the decrease of absolute lymphocyte levels, T lymphocytes (CD3) and T lymphocyte subsets (CD4 and CD8) in a dose-dependent manner. Ritlecitinib also promotes a decrease in NK cells (CD16/56), which remain stable up to week 48 after initiating treatment. In patients treated with 50 mg of ritlecitinib once a day, the decrease in median lymphocyte levels remains consistent up to week 48. At 12 times the mean maximum exposure of the 50 mg dose given to patients with alopecia areata once a day, ritlecitinib did not cause a clinically relevant effect on the QTc interval.[] The use of ritlecitinib is associated with the development of serious infections, malignancies (including non-melanoma skin cancer), major adverse cardiovascular events, thromboembolic events, and hypersensitivity. In the postmarketing safety study of another JAK inhibitor in patients with rheumatoid arthritis over 50 years of age with at least one cardiovascular risk factor, JAK inhibitors were associated with a higher rate of all-cause mortality, including sudden cardiovascular death, compared to TNF blockers.

Mechanism of Action · 1 item

Alopecia areata is an autoimmune disorder that causes hair loss mainly in the scalp but also on the face and other areas. In normal conditions, hair follicles are immune-privileged sites characterized by the presence of well-suppressed natural killer cells. However, disruptions to this system can lead to the loss of immune privilege and cause alopecia areata. Genome-wide association studies have linked the overexpression of UL16-binding protein 3 (ULBP3), a protein that binds to natural killer cell receptors, to the pathogenesis of alopecia areata. The overexpression of ULBP3 promotes the attack of cytotoxic cluster of differentiation 8-positive (CD8+) NK group 2D-positive (NKG2D+) T cells to hair follicles, leading to hair follicle dystrophy. CD8+ NKG2D+ T cells promote the inflammation of hair follicles through interferon-γ (IFN-γ) and interleukin-15 (IL-15) signaling pathways, which consequently activate Janus kinase (JAK)/signal transducer and activator of transcription (STAT) molecular pathways. Therefore, JAK inhibitors have been proposed for the treatment of alopecia areata. Ritlecitinib inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family in an irreversible manner by blocking the adenosine triphosphate (ATP) binding site. _In vitro_, ritlecitinib inhibits cytokine-induced STAT phosphorylation mediated by JAK3-dependent receptors and the signaling of immune receptors dependent on TEC kinase family members. Although it is possible that JAK inhibitors, such as ritlecitinib, inhibit the inflammatory pathways activated in alopecia areata, the precise mechanism of action has not been fully elucidated.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
1792180-81-4
PubChem CID
118115473
DTXSID
DTXSID301356920
ChEMBL
CHEMBL4085457
ChEBI
CHEBI:229233
UNII
2OYE00PC25
EC Number
815-269-7
Nikkaji
J3.684.821I
CBRJPFGIXUFMTM-WDEREUQCSA-N
SMILES
C(N1C[C@H](NC2N=CN=C3NC=CC3=2)CC[C@@H]1C)(=O)C=C
FDA UNII
2 OYE00PC25 · 2OYE00PC25
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338
WGK Germany
3 · WGK 3
Storage Class
11 · 11 - Combustible Solids
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P305+P351+P338
Biological Half-LifeRitlecitinib has a terminal half-life that ranges from 1.3 to 2.3 hours.
Metabolism/Metabolites · 1 item

Ritlecitinib is metabolized by cytochrome P450 (CYP) and glutathione-S-transferase (GST) enzymes. The GST enzymes participating in the metabolism of ritlecitinib include cytosolic GST A1/3, M1/3/5, P1, S1, T2, Z1 and microsomal GST 1/2/3, and the CYP enzymes participating in this process include CYP3A, CYP2C8, CYP1A2, and CYP2C9. No single route contributes to more than 25% of the total metabolism of ritlecitinib.

FDA Pharmacological Classification · 2 items

RITLECITINIB

Tyrosine Kinase Inhibitors [MoA]; Janus Kinase 3 Inhibitors [MoA]; Cytochrome P450 1A2 Inhibitors [MoA]; Kinase Inhibitor [EPC]; Cytochrome P450 3A Inhibitors [MoA]

MeSH Pharmacological Classification · 2 items

Agents that inhibit JANUS KINASES.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Absorption, Distribution and Excretion · 4 items

Up to 200 mg, the AUC0-tau and Cmax of ritlecitinib increase in an approximately dose-proportional manner, and steady state is reached approximately by day 4. Ritlecitinib has an absolute oral bioavailability of approximately 64%, and 1 hour after an oral dose is administered, peak plasma concentrations are achieved. Food does not have a clinically significant impact on the systemic exposures of ritlecitinib. The co-administration of a high-fat meal and a 100 mg ritlecitinib capsule reduced Cmax by 32% and increased AUCinf by 11%. Ritlecitinib was administered without regard to meals during clinical trials.

Ritlecitinib is mainly excreted through urine and feces. Approximately 66% and 20% of radiolabeled ritlecitinib are excreted in the urine and feces, respectively. Approximately 4% of the ritlecitinib dose is excreted unchanged drug in urine.

Ritlecitinib is predicted to have a volume of distribution of 1.3 L/kg.

Ritlecitinib is predicted to have a blood clearance of 5.6 mL/min/kg.

Applications · 2 items

UsesLooking at the history of alopecia areata drug development, ritlecitinib is the second mature drug for treating alopecia areata. It is a kinase inhibitor. Unlike the first drug, Olumiant, ritlecitinib is approved not only for adult patients but also for adolescents aged 12 and above.

DescriptionRitlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte’s Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.